Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Regulatory Predictability” Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says

Executive Summary

FDA's new leadership should focus on improving "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 4

You may also be interested in...



FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests

As agency issues take center stage at a pharmacoeconomics meeting, American Enterprise Institute fellow recommends reorganizing review divisions to accelerate approval of orphan drugs.

Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development

FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market

Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development

FDA's top review managers have a message for drug developers: they are eager to find creative ways to work with sponsors to bring new treatments for rare diseases to market

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS051179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel